Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery

Obesity Surgery

Volumn 22, Issue 5, 2012, Pages 783-790

  Matzko, Michelle E ^a,b   Argyropoulos, George ^a,c   Wood, G Craig ^a   Chu, Xin ^a,c   McCarter, Roger J M ^b   Still, Christopher D ^a   Gerhard, Glenn S ^a,c  

^a GEISINGER MEDICAL CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c WEIS CENTER FOR RESEARCH   (United States)

Author keywords

Ghrelin; RYGB; SNP; Weight loss

Indexed keywords

GHRELIN; GHRELIN RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETAGOGUE RECEPTOR TYPE 1A GENE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIVER LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEPTOR GENE; ROUX EN Y GASTRIC BYPASS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH BYPASS; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; FEMALE; GASTRIC BYPASS; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIVER; MALE; MIDDLE AGED; OBESITY, MORBID; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROMOTER REGIONS, GENETIC; RECEPTORS, GHRELIN; WEIGHT LOSS;

EID: 84862646748     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0631-2     Document Type: Article

References (54)

1. NIH NOEI: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: US Department of Health and Human Services, 1998
2. Asakawa A, Inui A, Kaga O, et al. Ghrelin is an appetitestimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337-45. (Pubitemid 32149296)
3. Borg C, Le Roux C, Ghatei M, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2005;93:210-5. (Pubitemid 43259607)
4. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247:401-7.
5. Cummings D, Purnell J, Frayo R, et al. A pre-prandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714-9. (Pubitemid 33641587)
6. Guan X, Yu H, Palyha O, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res. 1997;48:23-9. (Pubitemid 27298124)
7. Howard A, Feighner S, Cully D, et al. A receptor in the pituitary and hypothalamus that functions in growth hormone release. Science. 1996; 273:
8. Gnanapavan S, Kola B, Bustin S, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHSR1, in humans. J Clin Endocrin Metab. 2002;87:2988.
9. Sun Y, Wang P, Zheng H, et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004; 101:4679-84. (Pubitemid 38437470)
10. Tschoep M, Smiley D, Heiman M. Ghrelin induces adiposity in rodents. Nature. 2000;407:908-13.
11. Wren A, Seal L, Cohen M, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992-5. (Pubitemid 33152655)
12. Muccioli G, Tschöp M, Papotti M, et al. Neuroendocrine and peripheral activitiies of ghrelin: implications in metabolism and obesity. Eur J Pharmacology. 2002;440:235-54. (Pubitemid 34458027)
13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:
14. Morinigo R, Casamitjana V. Moize Vea. Short-term effects of gastric bypass surgery on circulating ghrelin levels Obesity Research. 2004;12:1108-16. (Pubitemid 41132490)
15. Leonetti F, Silecchia G. Different plasma ghrelin levels after laproscopic gastric bypass and adjustable gastric banding in morbid obese subjects. Clin Endocrin Metab. 2003;88:4227-31. (Pubitemid 37153724)
16. Lin E, Gletsu N, Fugate K. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg. 2004;139:780-4. (Pubitemid 38886515)
17. Fruehbeck G, Rotellar F. Hernandez-Lizoain Jea. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss of changes in insulinemia. Obes Surg. 2004;14:1208-15. (Pubitemid 39458595)
18. Geloneze B, Tambascia M, Pilla V, et al. Ghrelin: a gut-brain hormone. Effect of gastric bypass surgery. Obes Surg. 2003;13:17-22. (Pubitemid 36250233)
19. Tritos N, Mun E, Bertkau A, et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res. 2003;11:919-24. (Pubitemid 41137501)
20. Rodieux F, Giusti V, D'Alessio D, et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity. 2008;16:298-305. (Pubitemid 351271908)
21. Foschi D, Corsi F, Colombo F, et al. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients. J Investigative Surgery. 2008;21:77-81. (Pubitemid 351404804)
22. Le Roux C, Aylwin J, Batterham R. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic paramters. Ann Surg. 2006;243:108-14. (Pubitemid 43054062)
23. Le Roux CW, Welbourn R. Werling Mea. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780-5. (Pubitemid 350035654)
24. Faraj M, Havel P, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrin Metab. 2003;88:1594-692.
25. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and post-prandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrin Metab. 2005;90:359-65. (Pubitemid 40116682)
26. Korner J, Inabnet W, Febres G. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Rouxen-Y gastric bypass. Int J Obes. 2009;33:786-95.
27. Stoeckli R, Clianda R, Langer I, et al. Change of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 2004;12:346-50. (Pubitemid 41132559)
28. Couce M, Cottam D, Esplen J, et al. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg. 2006;16:870-8. (Pubitemid 44133475)
29. Whitson B, Leslie D, Kellogg T, et al. Enteroendocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surgical Research. 2007;141:31-9. (Pubitemid 46898439)
30. Liou J-M, Lin J-T, LeeW-J, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18:84-9.
31. Olivan B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009;249:948-53.
32. Vendrell J, Broch M, Vilarrasa N. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962-71.
33. Holdstock C, Engstrom B, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass sugery in obese humans. J Clin Endocrinol Metab. 2003;88:3177-83. (Pubitemid 36877491)
34. Sundbom M, Holdstock C, Engstrom B, et al. Early changes in ghrelin following Roux-en-Y gastric byapass: influence of vagal nerve functionality? Obes Surg. 2007;17:304-10. (Pubitemid 46659288)
35. Ybarra J, Bobbioni-Harsch E, Chassot G. Presistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric bypass-induced weight loss. Obes Surg. 2009;19:327-31.
36. Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida J, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg. 2008;18:1424-9.
37. Pournaras DJ, le Roux CW. Ghrelin and metabolic surgery. Int J Pept. 2012. pii 217267.
38. Baessler A, Fisher M, Mayer B, et al. Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease. Human Molec Genet. 2007;16:887-99. (Pubitemid 47062734)
39. Zavarella S, Petrone A, Zampetti S, et al. A new variation in the promoter region, the -604 C>T and the Leu72Met polymorphism of the ghrelin gene are associated with the protection to insulin resistance. Int J Obes. 2008;32:663-8. (Pubitemid 351536011)
40. den Hoed M, Smeets A, Veldhorst M, et al. SNP analyses of postprandial responses in (an)orexigenic hormones and feelings of hunger reveal long-term physiological adaptations to facilitate homeostasis. Int J Obes (Lond). 2008;32:1790-8.
41. Baessler A, Hasinoff M, Fischer M, et al. Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes. 2005;54:259-67. (Pubitemid 40105121)
42. Vartiainen J, Kesaniemi Y, Ukkola O. Sequencing analysis of the ghrelin gene 5′ flanking region: relations between the sequence variants, fasting plasma total ghrelin concentrations, and body mass index. Metabolism Clinical and Experimental. 2006;55:1420-5.
43. Mager U, Degenhardt T, Pulkkinen L, et al. Variations in the ghrelin receptor gene associate with obesity and glucose metabolism in individuals with impaired glucose tolerance. PLoS One. 2008;3:e2941.
44. Gueorguiev M, Lecoeur C, Meyre D, et al. Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obesity (Silver Spring). 2009;17:745-54.
45. Kleiner D, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21. (Pubitemid 40770284)
46. Chu X, Erdman R, Susek M, et al. Association of morbid obesity with FTO and INSIG2 allelic variants. Arch Surg. 2008;143:235-40. (Pubitemid 351439271)
47. Argyropoulos G, Rankinen T, Bai F, et al. The agouti-related protein and body fatness in humans. Int J Obes. 2003;27:276-80. (Pubitemid 36255812)
48. Bai F, Rankinen T, Charbonneau C, et al. Functional dimorphism of two hAgRP promoter SNPs in linkage disequillibrium. J Med Genet. 2004;41:350-3. (Pubitemid 38608517)
49. Ilnytska O, Stutz A, Park-York M, et al. Molecular mechanisms for activation of the agouti-related protein and stimulation of appetite. Diabetes. 2011;60:97-106.
50. Cummings D, Weigle D, Frayo R, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-30. (Pubitemid 34755670)
51. Kiewiet R, van Aken M, van der Weerd K, et al. Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol. 2009;161:567-73.
52. Dezaki K, Kakei M, Yada T. Ghrelin employs Gai2 and activates Kv channels to attenuate glucose-induced Ca2+ signaling and insulin resistance in islet B-cells: novel signal transduction of ghrelin. Diabetes. 2007;56:2319-27. (Pubitemid 47358239)
53. Leclercq I, Da Silva I, Morais A, et al. Insulin resistance in hepatocytes and siusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47:142-56. (Pubitemid 46830723)
54. Pittas A, Joseph N, Greenberg A. Adipocytokines and insulin resistance. J Clin Endocrin Metab. 2004;89:447-52. (Pubitemid 38269842)